PUMA BIOTECHNOLOGY, INC. | Intellectual Property | Business Contracts

Exclusive License Agreement, dated September 16, 2022, by and between the Company and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company... (Filed With SEC on November 3, 2022)

Amendment No. 3 to the License Agreement, dated February 24, 2021, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on May 6, 2021)

Amendment No. 2 to License Agreement dated October 29, 2020, between the Company and Pfizer Inc (Filed With SEC on March 1, 2021)

Amendment to the License Agreement, dated December 18, 2019, by and between the Company and Knight Therapeutics, Inc (Filed With SEC on February 28, 2020)

First Amendment to the License Agreement, dated September 17, 2019, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on February 28, 2020)

Second Amendment to the License Agreement, dated November 25, 2019, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on February 28, 2020)

License Agreement, dated March 29, 2019, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on May 10, 2019)

License Agreement, dated January 9, 2019, by and between the Company and Knight Therapeutics Inc (Filed With SEC on March 1, 2019)

PUMA BIOTECHNOLOGY, INC. (30) | Intellectual Property (8)